Market Overview

WD-40 Q3 Earnings Preview


WD-40 (NASDAQ: WDFC) unveils its next round of earnings this Tuesday, July 9. Get prepared with Benzinga's ultimate preview for WD-40's Q3 earnings.

Earnings and Revenue

Sell-side analysts expect WD-40's EPS to be near $1.22 on sales of $109 million.

WD-40 earnings in the same period a year ago was $1.15. Quarterly sales came in at $107.03 million. Revenue would be up 1.85% on a year-over-year basis. The company's reported EPS has stacked up against analyst estimates in the past like this:


Quarter Q2 2019 Q1 2019 Q4 2018 Q3 2018
EPS Estimate 1.11 0.95 0.99 1.05
EPS Actual 1.140 0.95 1.54 1.15

Stock Performance

For a full 12 months, the return has risen by 6.63%. Given that these returns are generally positive, long-term shareholders are probably relaxed going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. Analysts have been rating WD-40 stock as Neutral. The strength of this rating has maintained conviction over the past three months.

Conference Call

WD-40 is scheduled to hold a conference call at 5:00 p.m. ET and it can be accessed here:

Posted-In: Earnings News


Related Articles (WDFC)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

'Trading Nation' Breaks Down Under Armour, AMD, Starbucks And Hershey

The Daily Biotech Pulse: Roche Presents Positive Hemlibra Data, Amgen's Tender Offer For Nuevolution Complete, Genmab Offering